A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

ClinicalTrials.gov ID: NCT06147037

Public ClinicalTrials.gov record NCT06147037. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Study identification

NCT ID: NCT06147037
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Interventions

FPI-2053 Drug
[111In]-FPI-2107 Drug
[225Ac]-FPI-2068 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 30, 2024
Primary completion: May 11, 2028
Completion: May 11, 2028
Last update posted: Apr 27, 2026

2024 – 2028

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Research Site	Irvine	California	92618	Withdrawn
Research Site	Palo Alto	California	94304	Recruiting
Research Site	Santa Monica	California	90404	Not yet recruiting
Research Site	Chicago	Illinois	60637	Recruiting
Research Site	Boston	Massachusetts	02215	Recruiting
Research Site	St Louis	Missouri	63110	Withdrawn
Research Site	Omaha	Nebraska	68130	Recruiting
Research Site	Cleveland	Ohio	44195	Recruiting
Research Site	Pittsburgh	Pennsylvania	15237	Withdrawn
Research Site	Houston	Texas	77030	Recruiting
Research Site	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06147037, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06147037 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →